About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

XARACOLL

Latest News

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

23 Dec
DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and...
Read More

Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant

15 Apr
Results of implant’s safety, efficacy and pharmacokinetics for use in various open soft-tissue surgeries expected in first quarter 2022 April...
Read More

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

10 Feb
ATHLONE, Ireland – Feb. 4, 2021 – Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited